about
A new human immunodeficiency virus derived from gorillasThe Two-Phase Emergence of Non Pandemic HIV-1 Group O in Cameroon.Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.Non-M variants of human immunodeficiency virus type 1.Molecular epidemiology of simian immunodeficiency virus infection in wild-living gorillas.[Specific diagnosis and follow-up of HIV-1 group O infection: RES-O data].Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting.Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study.Genotypic resistance profiles of HIV-2-treated patients in West Africa.V3 serological subtyping of human immunodeficiency virus type 2 infection is not relevant.Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic.New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA loadBaseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide.National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.Viral etiology of respiratory tract infections in children at the pediatric hospital in Ouagadougou (Burkina Faso).HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrasePerformance of the Liaison XL Murex HIV Ab/Ag test on clinical samples representing current epidemic HIV variants.Characteristics of patients recently infected with HIV-1 non-B subtypes in France: a nested study within the mandatory notification system for new HIV diagnoses.Differential regulation of NF-κB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins.Plasma HIV-2 RNA According to CD4 Count Strata among HIV-2-Infected Adults in the IeDEA West Africa Collaboration.Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection.A Pan-HIV Strategy for Complete Genome Sequencing.V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1Multicenter quality control of hepatitis C virus protease inhibitor resistance genotypingA Multiplex PCR Approach for Detecting Dual Infections and Recombinants Involving Major HIV VariantsCensus and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections.Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.Higher specificity of nucleic acid sequence-based amplification isothermal technology than of real-time PCR for quantification of HIV-1 RNA on dried blood spots.Multiple HIV-1/M + HIV-1/O dual infections and new HIV-1/MO inter-group recombinant forms detected in Cameroon.Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCR.HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors.New Highly Sensitive Real-Time PCR Assay for HIV-2 Group A and Group B DNA Quantification.Simian Immunodeficiency Virus seroreactivity in inhabitants from rural Cameroon frequently in contact with non-human primates.Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG.[Respiratory syncytial virus (RSV) infections in the pediatric teaching hospital Charles de Gaulle of Ouagadougou, Burkina Faso].First evidence of transmission of an HIV-1 M/O intergroup recombinant virus.Interlaboratory quality control of total HIV-1 DNA load measurement for multicenter reservoir studies.Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.
P50
Q22251064-9CF97A98-651A-4538-930F-82063FFA7F8EQ30377499-932ED179-4CBA-4134-849E-280788912B28Q30397332-9DAA3652-4224-49A4-836E-0407884F8259Q30410687-4981AB8E-4EEA-4738-9BC4-6BAC184C28D6Q30432689-C282E096-734E-406A-BE22-873ABFD13571Q33614358-9BB181C3-F8E8-4277-9750-FCA6BD001E18Q33637041-1B41C0BD-CDDF-46D6-8B59-DEC4381BDFD4Q33640329-94414165-3B53-447B-AAE2-EEFB3214D93DQ33825378-2AA459C9-9309-4AC1-92C4-661D6602220FQ33954546-A0C00DB5-C9FF-4FA9-959F-64C3C316893FQ33973817-F4DFA166-F095-484A-95AF-34F079AF5DDDQ33995146-86DAC463-063E-4697-B48C-46BC9E84DD9AQ34058765-89A792A9-C61F-48F7-9E0E-D85014F76E77Q34108713-BEC3E3F5-A0A3-4845-9A5B-7EB588A88807Q34353387-EEDF6701-65EB-49F0-8DA5-36C9B4C4492DQ34434331-1F1FE110-E63A-4356-B4DE-335799D1BACDQ34597650-1B3E7EB9-3A69-44BA-8768-7D0E92E20ADEQ35035727-7AED2884-6ADE-4DBB-AB2B-990033013C41Q35036046-BF6E1ED9-DF74-4F41-8725-3EA5AAF8DCC1Q35549043-82EA9024-EB70-45D6-8D46-802FC90E7B26Q35674666-19F7CCF7-FDB3-40D3-8BB8-01AB47E666E1Q35757761-26BFABA8-0074-4F3F-9F18-3E1D4D53ECEFQ35807096-307B003E-4A0E-4D29-94BE-B0F9C98D92BDQ35877301-0844F7C9-D388-4D2E-96B2-F6667FDC77C5Q36628369-AE02D782-6912-47CF-9CE0-C9F8D3DD69A0Q36826639-B0DEDFD5-39FC-4B42-8CB2-4C351A708E11Q36834771-D35FBCDD-0689-4415-AC1B-129B29FEF062Q37333651-B78EF71E-1488-4478-A676-E6EA986B6D77Q37336742-ED918F08-8172-4286-B34E-5308A7D9C450Q37546718-C823E056-FEEB-49AA-ADAF-D06F3C550988Q37586704-FCD5F1F0-8BB0-4378-B458-271376ED5740Q37703311-9E8AE591-77B8-4A12-9F2D-AD4A1B1D1AA4Q38599565-8512FFED-B698-4D44-822A-ADDD6B52D4AEQ38682063-6EFDDF6E-6DCF-403A-A19F-F66AA7827A97Q39004450-BCCE95E5-C3E3-4C58-AB78-77846D29A88FQ39626666-AA315D5B-9845-4CAD-AE96-CDCFCE18DFA6Q40120543-FB8C6ACA-1E18-4D9E-B872-81A9E3331AE9Q40144635-74271782-3EB4-4AC2-891A-A69D8EDF41D9Q40158843-E655F3B1-8ED0-4D92-A2B6-F672BED4B666Q40278469-44A67109-4E23-4D70-B7CF-1FC79258C37B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jean-christophe Plantier
@ast
Jean-christophe Plantier
@en
Jean-christophe Plantier
@es
Jean-christophe Plantier
@nl
Jean-christophe Plantier
@sl
type
label
Jean-christophe Plantier
@ast
Jean-christophe Plantier
@en
Jean-christophe Plantier
@es
Jean-christophe Plantier
@nl
Jean-christophe Plantier
@sl
prefLabel
Jean-christophe Plantier
@ast
Jean-christophe Plantier
@en
Jean-christophe Plantier
@es
Jean-christophe Plantier
@nl
Jean-christophe Plantier
@sl
P106
P21
P31
P496
0000-0001-6417-4083